Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation--an economic analysis based on the ESPOIR cohort.

Chevreul K, Haour G, Lucier S, Harvard S, Laroche ML, Mariette X, Saraux A, Durand-Zaleski I, Guillemin F, Fautrel B.

PLoS One. 2014 May 8;9(5):e97077. doi: 10.1371/journal.pone.0097077. eCollection 2014.

2.
3.

Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.

Zhu B, Edson-Heredia E, Gatz JL, Guo J, Shuler CL.

Clin Ther. 2013 Sep;35(9):1376-85. doi: 10.1016/j.clinthera.2013.07.328. Epub 2013 Aug 15.

PMID:
23954091
4.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):377-93.

PMID:
15853437
5.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
6.

Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.

Kvamme MK, Lie E, Kvien TK, Kristiansen IS.

Rheumatology (Oxford). 2012 Sep;51(9):1618-27. doi: 10.1093/rheumatology/kes074. Epub 2012 Apr 25.

7.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

8.

Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?

Ciubotariu E, Gabay C, Finckh A; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

J Rheumatol. 2014 Aug;41(8):1576-82. doi: 10.3899/jrheum.130767. Epub 2014 Jul 15.

PMID:
25028383
9.
10.

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.

Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.

Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.

PMID:
19884622
11.

Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Katchamart W, Trudeau J, Phumethum V, Bombardier C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008495. doi: 10.1002/14651858.CD008495. Review.

PMID:
20393970
12.
14.

Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.

Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.

J Rheumatol. 2013 Oct;40(10):1650-7. doi: 10.3899/jrheum.121515. Epub 2013 Aug 15.

PMID:
23950185
15.

Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.

Roussy JP, Bessette L, Bernatsky S, Rahme E, Lachaine J.

Osteoporos Int. 2013 Sep;24(9):2483-92. doi: 10.1007/s00198-013-2321-x. Epub 2013 Mar 16.

PMID:
23504029
16.

Inequities in access to biologic and synthetic DMARDs across 46 European countries.

Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’.

Ann Rheum Dis. 2014 Jan;73(1):198-206. doi: 10.1136/annrheumdis-2012-202603. Epub 2013 Mar 6.

PMID:
23467636
17.

Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.

Kim SC, Yelin E, Tonner C, Solomon DH.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1529-33. doi: 10.1002/acr.21997.

18.

Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.

McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA.

J Rheumatol. 2011 Oct;38(10):2141-9. doi: 10.3899/jrheum.101195. Epub 2011 Aug 15.

PMID:
21844154
19.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

20.

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.

Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S.

Arthritis Rheum. 2006 Sep;54(9):2757-64. Erratum in: Arthritis Rheum. 2006 Oct;54(10):3134.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk